GlobeStar Therapeutics Corporation (GSTC)

GlobeStar Therapeutics Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Revenue	-	-	-	-	0	0
Revenue Growth (YoY)	-	-	-	-	-81.88%	-52.25%
Cost of Revenue	-	-	-	0	0.04	0
Gross Profit	-	-	-	-0	-0.04	0
Selling, General & Admin	0.8	1.86	1.27	9.09	0.27	0.32
Operating Expenses	0.8	1.86	1.27	9.09	0.27	0.32
Operating Income	-0.8	-1.86	-1.27	-9.09	-0.3	-0.32
Interest Expense	-0.08	-0.09	-0.07	-0.29	-0.24	-0.36
EBT Excluding Unusual Items	-0.89	-1.96	-1.34	-9.38	-0.54	-0.68
Gain (Loss) on Sale of Investments	-	-	-	-	-	-0.01
Other Unusual Items	-	0.01	-0.15	-0.42	-	0.01
Pretax Income	-0.89	-1.95	-1.49	-9.8	-0.54	-0.68
Earnings From Continuing Operations	-0.89	-1.95	-1.49	-9.8	-0.54	-0.68
Net Income	-0.89	-1.95	-1.49	-9.8	-0.54	-0.68
Preferred Dividends & Other Adjustments	0.03	-	-	-	-	1.6
Net Income to Common	-0.92	-1.95	-1.49	-9.8	-0.54	-2.28
Shares Outstanding (Basic)	1,069	827	629	482	298	105
Shares Outstanding (Diluted)	1,069	827	629	482	298	105
Shares Change (YoY)	39.10%	31.63%	30.38%	61.73%	184.50%	85.40%
EPS (Basic)	-0.00	-0.00	-0.00	-0.02	-0.00	-0.02
EPS (Diluted)	-0.00	-0.00	-0.00	-0.02	-0.00	-0.02
Free Cash Flow	-0.15	-0.21	-0.33	-0.75	-0.24	-0.26
Free Cash Flow Per Share	-	-	-0.00	-0.00	-0.00	-0.00
Gross Margin	-	-	-	-	-	63.77%
Operating Margin	-	-	-	-	-394377.92%	-74322.35%
Profit Margin	-	-	-	-	-703546.75%	-535311.06%
Free Cash Flow Margin	-	-	-	-	-313658.44%	-61208.94%
EBITDA	-	-	-1.26	-9.09	-0.3	-0.32
D&A For EBITDA	-	-	0	0	0	0
EBIT	-0.8	-1.86	-1.27	-9.09	-0.3	-0.32

Updated Oct 11, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.